CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 472 enrolled
Drug / intervention
Rivaroxaban +1 moredrug
Likely dose
Rivaroxaban 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01499953
NCT01499953Phase 3Completed
CompareCT.gov

Superficial Vein Thrombosis (SVT) Treated for Forty-five Days With Rivaroxaban Versus Fondaparinux

GWT-TUD GmbH·interventional·Posted Dec 26, 2011·Updated May 15, 2023

In Brief

A Phase 3 clinical trial evaluating Rivaroxaban and Fondaparinux for Superficial Vein Thrombosis. Completed, enrolled 472 participants across 23 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus fondaparinux in the treatment of superficial vein thrombosis (SVT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSuperficial Vein Thrombosis
CountriesGermany
CollaboratorsBayer

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 26, 2011
Enrollment StartApr 1, 2012
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 14.5 years ago

Interventions

Rivaroxabandrug

Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral

Fondaparinuxdrug

Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous